Abstrakt

Aim: Ankylosing spondylitis (AS), a chronic inflammatory arthritis, is strongly associated with HLA-B27 gene worldwide. Among immunocyte receptors reacting with HLA-B27 are killer cell immunoglobulin-like receptors (KIRs ), particularly KIR3DL1 and KIR3DL2. The KIR family includes both activating and inhibitory receptors. These may be expressed on NK cells and subtypes of T cells, which via activating/inhibitory signals regulate the activity of immunocompetent cells and potentially have an impact on inflammation and autoimmunity occurrence. However, reports on the role of KIRs in AS are controversial. Material/Methods: We examined the possible associations of KIR genes in 192 patients diagnosed with AS compared with 191 control individuals. KIR genes were typed using PCR-SSP method. Results: No single KIR gene frequency was found to differ between patients and controls. Nevertheless, the genotypes containing three genes encoding activating KIRs, as well as those characterized by ratios of activating to inhibitory KIRs close to 1:2 (0.5–0.6) were significantly less frequent in AS than in controls. On the contrary, higher ratios (0.67–1.67) were more frequent in AS in comparison to controls. Conclusions: Our results suggest a protective effect of the presence of 3 (but not more) genes encoding activating KIRs, and of a ratio of activating to inhibitory KIRs close to 1:2 (0.5–0.6) but not higher. On the other hand, higher activating to inhibitory KIR ratios seem to predispose to AS. This suggests a very narrow window for optimal ratio of activating to inhibitory KIRs.

Przypisy

• 1. Abdullah H., Zhang Z., Yee K., Haroon N.: KIR3DL1 interactionwith HLA-B27 is altered by ankylosing spondylitis associatedERAP1 and enhanced by MHC class I cross-linking. Discov. Med.,2015; 20(108): 79-89
  Google Scholar
• 2. Campbell K.S., Purdy A.K.: Structure/function of human killercell immunoglobulin-like receptors: lessons from polymorphisms,evolution, crystal structures and mutations. Immunology, 2011;132(3): 315-25
  Google Scholar
• 3. Carrington M., Norman P.: The KIR Gene Cluster. National Library of Medicine (US), National Center for Biotechnology Information: Bethesda, MD. https://www.ncbi.nlm.nih.gov/books/NBK10135/ (15.03.2018)
  Google Scholar
• 4. Cauli A., Piga M., Dessole G., Porru G., Floris A., Vacca A., Desogus E., La Nasa G., Mathieu A.: Killer-cell immunoglobulin-like receptors (KIR) and HLA-class I heavy chains in ankylosing spondylitis. Drug Dev. Res., 2014; 75(Suppl. 1): S15-S19
  Google Scholar
• 4. alleles with susceptibility to ankylosing spondylitis.Arthritis Rheum., 2010; 62(4): 1000-6
  Google Scholar
• 5. Cauli A., Shaw J., Giles J., Hatano H., Rysnik O., Payeli S., McHugh K., Dessole G., Porru G., Desogus E., Fiedler S., Hölper S., Carette A., Blanco- Gelaz M.A., Vacca A., et al.: The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09. Rheumatology, 2013; 52(11): 1952-62
  Google Scholar
• 6. Conigliaro P., Scrivo R., Valesini G., Perricone R.: Emerging rolefor NK cells in the pathogenesis of inflammatory arthropathies.Autoimmun. Rev., 2011; 10(10): 577-81
  Google Scholar
• 7. Díaz-Peña R., Blanco-Gelaz M.A., López-Larrea C.: KIR genes andtheir role in spondyloarthropathies. Adv. Exp. Med. Biol., 2009; 649:286-99
  Google Scholar
• 8. Diaz-Pena R., Blanco-Gelaz M.A., Suarez-Alvarez B., Martinez-Borra J., Lopez-Vazquez A., Alonso-Arias R., Brüges-Armas J., Vidal-Castiñeira J.R., López-Larrea C.: Activating KIR genes are associatedwith ankylosing spondylitis in Asian populations. Hum. Immunol.,2008; 69(7): 437-442
  Google Scholar
• 9. Diaz-Pena R., Vidal-Castineira J.R., Alonso-Arias R., Suarez-AlvarezB., Vicario J.L., Solana R., Collantes E., López-Vázquez A., Martínez-Borra J., López-Larrea C.: Association of the KIR3DS1
  Google Scholar
• 10. Diaz-Pena R., Vidal-Castiñeira J.R., Mulero J., Sánchez A., QueiroR., López-Larrea C.: Activating killer immunoglobulin-like receptorsgenes are associated with increased susceptibility to ankylosingspondylitis. Clin. Exp. Immunol., 2015; 180(2): 201-6
  Google Scholar
• 11. Espeli M., Niederer H.A., Traherne J.A., Trowsdale J., Smith K.G.:Genetic variation, Fcγ receptors, KIRs and infection: the evolution ofautoimmunity. Curr. Opin. Immunol., 2010; 22: 715-722
  Google Scholar
• 12. Garg N., van den Bosch F., Deodhar A.: The concept of spondyloarthritis:Where are we now? Best Pract. Res. Clin. Rheumatol., 2014;28(5): 663-672
  Google Scholar
• 13. Gianchecchi E., Delfino D.V., Fierabracci A.: NK cells in autoimmunediseases: Linking innate and adaptive immune responses. Autoimmun.Rev., 2018; 17(2): 142-154
  Google Scholar
• 14. Harvey D., Pointon J.J., Sleator C., Meenagh A., Farrar C., Sun J.Y.,Senitzer D., Middleton D., Brown M.A., Wordsworth B.P.: Analysis ofkiller immunoglobulin-like receptor genes in ankylosing spondylitis.Ann. Rheum. Dis., 2009; 68(4): 595–8
  Google Scholar
• 15. Jiao Y.L., Ma C.Y., Wang L.C., Cui B., Zhang J., You L., Chen Z.J., Li J.F.,Zhao Y.R.: Polymorphisms of KIRs gene and HLA-C alleles in patientswith ankylosing spondylitis: possible association with susceptibilityto the disease. J. Clin. Immunol., 2008; 28(4): 343–9
  Google Scholar
• 16. Jiao Y.L., Zhang B.C., You L., Li J.F., Zhang J., Ma C.Y., Cui B., WangL.C., Chen Z.J., Zhao Y.R.: Polymorphisms of KIR gene and HLA-C alleles:possible association with susceptibility to HLA-B27-positive patientswith ankylosing spondylitis. J. Clin. Immunol., 2010; 30(6): 840–4
  Google Scholar
• 17. Kuśnierczyk P., Majorczyk E.: Pas de quatre: an interaction of HLA-B*27:05 and KIR3DL2 homodimers in spondyloarthropathies. Rheumatology, 2013; 52(11): 1931–2
  Google Scholar
• 18. Laval S.H., Timms A., Edwards S., Bradbury L., Brophy S., Milicic A., Rubin L., Siminovitch K.A., Weeks D.E., Calin A., Wordsworth P.B., Brown M.A.: Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am. J. Hum. Genet., 2001; 68(4): 918–26
  Google Scholar
• 19. Li Z., Brown M.A.: Progress of genome-wide association studiesof ankylosing spondylitis. Clin. Transl. Immunology, 2017; 6(12): e163
  Google Scholar
• 20. Lopez-Larrea C., Blanco-Gelaz M.A., Torre-Alonso J.C., BrugesArmas J., Suarez-Alvarez B., Pruneda L., Couto A.R., Gonzalez S., Lopez-Vázquez A., Martinez-Borra J.: Contribution of KIR3DL1/3DS1 toankylosing spondylitis in human leukocyte antigen-B27 Caucasianpopulations. Arthritis Res. Ther., 2006; 8(4): R101–R105
  Google Scholar
• 21. Mahmoudi M., Jamshidi A.R., Karami J., Mohseni A., AmirzargarA.A., Farhadi E., Ahmadzadeh N., Nicknam M.H.: Analysis of killer cellimmunoglobulin-like receptor genes and their HLA ligands in Iranianpatients with ankylosing spondylitis. Iran. J. Allergy Asthma Immunol.,2016; 15(1): 27–38
  Google Scholar
• 22. Majorczyk E., Pawlik A., Łuszczek W., Nowak I., Wiśniewski A., JasekM., Kuśnierczyk P.: Associations of killer cell immunoglobulin-likereceptor genes with complications of rheumatoid arthritis. GenesImmun., 2007; 8(8): 678–83
  Google Scholar
• 23. Martin A.M., Kulski J.K., Gaudieri S., Witt C.S., Freitas E.M., TrowsdaleJ., Christiansen F.T.: Comparative genomic analysis, diversity andevolution of two KIR haplotypes A and B. Gene, 2004; 335: 121–31
  Google Scholar
• 24. Mousavi T., Poormoghim H., Moradi M., Tajik N., Shahsavar F., AsadifarB.: Inhibitory killer cell immunoglobulin-like receptor KIR3DL1in combination with HLA-B Bw4Iso protect against ankylosing spondylitis.Iran. J. Immunol., 2010; 7(2): 88–95
  Google Scholar
• 25. Niepiekło-Miniewska W., Majorczyk E., Matusiak Ł., GendzekhadzeK., Nowak I., Narbutt J., Lesiak A., Kuna P., Ponińska J., Pietkiewicz–Sworowska A., Samoliński B., Płoski R., Szepietowski J.C., Senitzer D.,Kuśnierczyk P.: Protective effect of the KIR2DS1 gene in atopic dermatitis.Gene, 2013; 527(2): 594–600
  Google Scholar
• 26. Nowak I., Majorczyk E., Wiśniewski A., Pawlik A., Magott-ProcelewskaM., Passowicz-Muszyńska E., Malejczyk J., Płoski R., GiebelS., Barcz E., Zoń-Giebel A., Malinowski A., Tchórzewski H., ChlebickiA., Łuszczek W., et al.: Does the KIR2DS5 gene protect from somehuman diseases? PLoS One, 2010; 5(8): e12381
  Google Scholar
• 27. Parham P.: MHC class I molecules and KIRs in human history,health and survival. Nat. Rev. Immunol., 2005; 5(3): 201–14
  Google Scholar
• 28. Qin H., Wang Z., Du W., Lee W.H., Wu X., Riggs A.D., Liu C.P.:Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhancesinhibition of type 1 diabetes by autoantigen-specific regulatory Tcells. Proc. Natl. Acad. Sci. USA, 2011; 108(5): 2016–21
  Google Scholar
• 29. Shastry A., Sedimbi S.K., Rajalingam R., Rumba I., Kanungo A.,Sanjeevi C.B.: Different KIRs confer susceptibility and protectionto adults with latent autoimmune diabetes in Latvian and AsianIndian populations. Ann. NY Acad. Sci., 2008; 1150: 133–8
  Google Scholar
• 30. Shaw J., Kollnberger S.: New perspectives on the ligands andfunction of the killer cell immunoglobulin-like receptor KIR3DL2in health and disease. Front. Immunol., 2012; 3: 339
  Google Scholar
• 31. Tajik N., Shahsavar F., Poormoghim H., Radjabzadeh M.F., MousaviT., Jalali A.: KIR3DL1+HLA-B Bw4Ile80 and KIR2DS1+HLA-C2combinations are both associated with ankylosing spondylitis inthe Iranian population. Int. J. Immunogenet., 2011; 38(5): 403–9
  Google Scholar
• 32. Vendelbosch S., Heslinga S.C., John M., van Leeuwen K., GeisslerJ., de Boer M., Tanck M.W., van den Berg T.K., Crusius J.B., van derHorst-Bruinsma I.E., Kuijpers T.W.: Study on the protective effectof the KIR3DL1 gene in ankylosing spondylitis. Arthritis Rheumatol.,2015; 67(11): 2957–65
  Google Scholar
• 33. Vilches C., Castaño J., Gómez-Lozano N., Estefanía E.: Facilitationof KIR genotyping by a PCR-SSP method that amplifies shortDNA fragments. Tissue Antigens, 2007; 70(5): 415-422
  Google Scholar
• 34. Wang S., Li G., Ge R., Duan Z., Zeng Z., Zhang T., Gao J., YangT., Liu S., Wu S., Fan D., Xu S., Xu J., Zhang L., Shuai Z., et al.: Associationof KIR genotype with susceptibility to HLA-B27-positiveankylosing spondylitis. Mod. Rheumatol. 2013; 23(3): 538–41
  Google Scholar
• 35. Wong-Baeza I., Ridley A., Shaw J., Hatano H., Rysnik O., McHughK., Piper C., Brackenbridge S., Fernandes R., Chan A., Bowness P.,Kollnberger S.: KIR3DL2 binds to HLA-B27 dimers and free H chainsmore strongly than other HLA class I and promotes the expansionof T cells in ankylosing spondylitis. J. Immunol. 2013; 190(7):3216–24
  Google Scholar
• 36. Yen J.H., Moore B.E., Nakajima T., Scholl D., Schaid D.J., WeyandC.M., Goronzy J.J.: Major histocompatibility complex class I-recognizingreceptors are disease risk genes in rheumatoid arthritis.J. Exp. Med., 2001; 193(10): 1159–67
  Google Scholar
• 37. Zambrano-Zaragoza J.F., Agraz-Cibrian J.M., Gonzalez-ReyesC., Duran-Avelar Mde J., Vibanco-Perez N.: Ankylosing spondylitis:from cells to genes. Int. J. Inflam., 2013; 2013: 501653
  Google Scholar
• 38. Zvyagin I.V., Mamedov I.Z., Britanova O.V., Staroverov D.B.,Nasonov E.L., Bochkova A.G., Chkalina A.V., Kotlobay A.A., KorostinD.O., Rebrikov D.V., Lukyanov S., Lebedev Y.B., Chudakov D.M.:Contribution of functional KIR3DL1 to ankylosing spondylitis. Cell.Mol. Immunol., 2010; 7(6): 471–6
  Google Scholar

Pełna treść artykułu